Table 3.
Adalimumab trough serum concentrations during induction and maintenance treatment
| Treatment | Remission status at week 8 | Mean, μg/mL ± SD (Min–Max), N nmiss | Remission status at week 52 | Mean, μg/mL ± SD (Min–Max), N nmiss | |||
|---|---|---|---|---|---|---|---|
| Week | Week | ||||||
| 2 | 4 | 8 | 32 | 52 | |||
| ADA 80/40 mg | Yes (n = 12) | 5.51 ± 2.19 (1.18–8.14), 12 | 4.96 ± 2.59 (0.92–8.41), 12 | 5.97 ± 2.69 (0.82–10.4), 12 | Yes (n = 23) | 9.38 ± 5.50 (3.99–24.8), 23 | 9.19 ± 3.69 (3.56–16.8), 23 |
| No (n = 75) | 6.29 ± 1.68 (3.65–12.1), 75 | 5.65 ± 2.30 (0–10.9), 74 | 6.19 ± 3.03 (0–12.5), 72 | No (n = 37)a | 7.31 ± 4.46 (0–17.0), 25 | 7.77 ± 5.23 (0–16.7), 19 | |
| ADA 160/80 mg | Yes (n = 9) | 13.2 ± 3.12 (8.19–17.6), 9 | 13.9 ± 2.90 (9.71–17.7), 9 | 11.1 ± 3.16 (5.77–16.9), 9 | Yes (n = 18) | 10.1 ± 3.28 (4.16–16.7), 18 | 9.44 ± 3.62 (0.55–16.6), 16 |
| No (n = 81)b | 13.4 ± 4.58 (3.60–30.4), 80 | 13.3 ± 5.16 (0–31.6), 79 | 9.15 ± 5.03 (0–24.7), 77 | No (n = 48)c | 6.63 ± 5.28 (0–18.5), 35 | 7.07 ± 5.25 (0–17.4), 33 | |
ADA adalimumab, N nmiss number of nonmissing observations, SD standard deviation
aTwenty-seven patients who entered the rescue arm were excluded
bOne patient was incorrectly rescued at week 0 and excluded from analysis
cTwenty-four patients who entered the rescue arm were excluded